Dr. Stevens leads a group of more than 20 investigators at Synthetic Genomics to develop next-generation technologies for organ xenotransplantation, as part of a collaboration with the Lung Biotechnology subsidiary of United Therapeutics. He previously led the design, creation and use of complex genetically-modified mammalian platforms for discovery of biologic and cell-based therapies and disease modeling. Throughout the course of his career in biotechnology, Dr. Stevens and his teams have applied advanced genomic engineering to meet a range of crucial health needs. Notably, he’s helped develop FDA-approved antibody therapies and has created platforms for antibody discovery that are now widely used at top pharma companies worldwide.
An inventor on more than 200 U.S. patents and applications, Dr. Stevens is the author of numerous peer-reviewed scientific articles and book chapters, and speaks at conferences worldwide. He previously served as co-principal investigator on a Gates Foundation Grand Challenges in Global Health grant and currently acts as scientific consultant for biotech and pharma companies and investor groups, as well as a member of the Scientific Advisory Board for Siamab Therapeutics. Dr. Stevens holds a B.S. in Biology from Bucknell University and a Ph.D. in Molecular Biology from University of Pennsylvania.